News Center

位置：

Honors Announcement

Group News

Media Reports

Siyao and Bosheng Win Multiple Awards from the China Pharmaceutical Packaging Association

Category:

Honors Announcement

发布时间：2019-05-14

【概要描述】 The China Pharmaceutical Packaging Association organized the “Forty Years of Standing Together Through Thick and Thin in China’s Pharmaceutical Packaging Industry” recognition event, at which our company was awarded the “Outstanding Member Gold Award.” Our Chairman, Qu Jiguang, received the “Special Contribution Award,” while our Chief Engineer and Director of the Pharmaceutical Research Institute, Yin Dianshu, was honored with the “Outstanding Achievement Award” and named a “Leader in the Industry for Forty Years of Standing Together Through Thick and Thin.” In addition, Jiangsu Bosheng Medical New Materials Co., Ltd. was presented with the “Outstanding Member Leadership Award,” and its Chairman, Zhang Lüyi, and Chief Engineer, Zhang Enbo, were both awarded the “Special Contribution Award.”

In 2019, the China Pharmaceutical Packaging Association celebrated its 40th anniversary. Over the past four decades, amid the sweeping tide of reform and opening-up, the pharmaceutical packaging industry has consistently advanced in tandem with the pharmaceutical manufacturing sector, achieving substantial growth in both scale and technological sophistication. To recognize the outstanding contributions made during this period by member enterprises and individuals to the development of the industry and the Association’s own growth, the China Pharmaceutical Packaging Association organized the “Forty Years of Standing Together Through Thick and Thin in China’s Pharmaceutical Packaging” recognition event.

Recently, the 10th Members’ Conference and Symposium on Pharmaceutical Packaging Policies and Technologies, hosted by the China Pharmaceutical Packaging Association, was held in Haikou, where the results of the recognition awards were announced. The company was honored with the “Outstanding Member Gold Award,” while its Chairman, Qu Jiguang, received the “Special Contribution Award.” Yin Dianshu, the company’s Chief Engineer and Director of the Pharmaceutical Research Institute, was presented with both the “Outstanding Achievement Award” and the title of “Industry Leader Who Has Walked the Journey Together Through Thick and Thin for Forty Years.” In addition, Jiangsu Bosheng Medical New Materials Co., Ltd. was awarded the “Outstanding Member Leadership Award,” and its Chairman, Zhang Lüyi, and Chief Engineer, Zhang Enbo, were each recognized with the “Special Contribution Award.”

In recent years, the company has focused on key technological development trends in the pharmaceutical packaging materials and pharmaceutical industries, vigorously promoting industry–university–research collaboration. It has established a quality control system and standards for raw materials at the very source of medical packaging material production, actively aligned its practices with international advanced standards such as those of the FDA and the European Union, and driven the development and upgrading of domestic standards in the pharmaceutical packaging sector. To date, the company has either led or participated in the formulation of a total of 22 national and industry standards.

Jiangsu Bosheng Medical New Materials Co., Ltd. has established a comprehensive product value chain and portfolio that encompasses independent R&D and industrialization of new medical packaging materials, the application of pharmaceutical packaging materials, and pharmaceutical development and manufacturing. The company has obtained 45 drug packaging material registration certificates issued by the National Medical Products Administration of China and has achieved breakthroughs in eight technologies that fill domestic gaps. Several proprietary products, including bromobutyl rubber stoppers specially formulated for ceftriaxone sodium, poly(p-xylene)-coated bromobutyl rubber stoppers, and coated butyl rubber stoppers in multiple specifications, have been registered with the U.S. DMF, with quality meeting internationally advanced standards. In addition, numerous products have been recognized as National Key New Products and Jiangsu Provincial High-Tech Products and have been included in the National Torch Program.

Keywords:

The company’s 150 mg fluconazole tablets are the first in China to pass the consistency evaluation.

The company was rated as a Tax Credit Grade A taxpayer for 2018.

The company’s 150 mg fluconazole tablets are the first in China to pass the consistency evaluation.

The company was rated as a Tax Credit Grade A taxpayer for 2018.